Singpore, April 10 -- Sino Biopharmaceutical Group has entered into a strategic partnership with Germany-headquartered Boehringer Ingelheim to bring Boehringer Ingelheim's innovative cancer therapies to the market in mainland China.

Under the agreement, Sino Biopharma and Boehringer Ingelheim will collaborate to jointly develop and commercialise Boehringer Ingelheim's oncology pipeline in mainland China. The strategic partnership covers multiple assets under clinical development by Boehringer Ingelheim, including three assets brigimadlin, zongertinib, and BI 764532, and multiple early-stage assets.

The companies will join efforts to bring these oncology products to patients in mainland China, with the Sino consolidating the revenue for ...